SCHEMBL13783473

SCHEMBL13783473

CCC1CCCN(C(=O)CN(C)C)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ ALDH1A1 P00352 4/20 0.41
▸ LMNA P02545 1/20 0.41
▸ JAK3 P52333 3/20 0.41
▸ JAK2 O60674 3/20 0.41
▸ JAK1 P23458 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.38
▸ DPP8 Q6V1X1 1/20 0.36
▸ DPP7 Q9UHL4 1/20 0.36
▸ PAX8 Q06710 1/20 0.36
▸ ITGB3 P05106 2/20 0.36
▸ ITGA2B P08514 2/20 0.36
▸ F2R P25116 1/20 0.35
▸ CTSD P07339 2/20 0.35
▸ BACE1 P56817 2/20 0.35
▸ PREP P48147 1/20 0.35
▸ HSD11B1 P28845 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22732723 1.00 MEN1 (0.42) MEN1POLBMAPTKMT2AALDH1A1
SCHEMBL24456619 0.92 DPP8 (0.42) MEN1POLBMAPTKMT2AALDH1A1
SCHEMBL25477547 0.92 DPP8 (0.42) MEN1POLBMAPTKMT2AALDH1A1
SCHEMBL21430432 0.86 JAK3 (0.42) MEN1POLBMAPTKMT2AALDH1A1
SCHEMBL21430657 0.86 JAK3 (0.42) MEN1POLBMAPTKMT2AALDH1A1
SCHEMBL22732600 0.86 JAK3 (0.42) MEN1POLBMAPTKMT2AALDH1A1
SCHEMBL23710028 0.85 ITGB3 (0.43) MEN1POLBMAPTKMT2AALDH1A1
SCHEMBL21430433 0.83 ITGB3 (0.41) MEN1POLBMAPTKMT2AALDH1A1
SCHEMBL13686205 0.83 MEN1 (0.46) MEN1POLBMAPTKMT2AALDH1A1
SCHEMBL21581035 0.81 POLB (0.45) MEN1POLBMAPTKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220220110-A1 METHYL- AND TRIFLUOROMETHYL-CONTAINING DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITOR CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2022-07-14 — — US disclosed
EP-3858832-A1 TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2021-08-04 — — EP disclosed
US-20090176307-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. 2009-07-09 — — US disclosed
US-7399866-B2 Compounds, compositions, and methods CYTOKINETICS, INC. (US) 2008-07-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220220110-A1 METHYL- AND TRIFLUOROMETHYL-CONTAINING DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITOR BCL2L11, BCL2, BCL2L1 MEN1 3412/4885POLB 2824/4885MAPT 3272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback